SCGE
banner
scge.bsky.social
SCGE
@scge.bsky.social
The Somatic Cell Genome Editing (SCGE) Consortium is an NIH Common Fund program that aims to develop safe and effective methods to perform gene editing to treat genetic diseases in somatic cells. Reposts/likes do not equal endorsements.
scge.mcw.edu
Richard Lewis, PhD is the Principal Regulatory Device & Biologics Expert at Hyman, Phelps & McNamara, P.C.

More info about the SCGE Meet the Expert series can be found at scge.mcw.edu/meet-the-exp...

#RegulatoryGuidance #RareDisease #Preclinical #Biotech #BiomedicalResearch
November 12, 2025 at 2:36 PM
James Valentine, JD, MHS is a Director at Hyman, Phelps & McNamara, P.C. where he assists medical product industry and patient advocacy organization clients in a wide range of regulatory matters relating to new drug and biologic development and approval.
November 12, 2025 at 2:36 PM
With enhanced targeting versatility, Flex-Cas12a unlocks access to previously inaccessible genomic loci, providing new opportunities for both therapeutic and agricultural genome engineering. (3/3)

#Research #CRISPR #GeneEditing
November 11, 2025 at 3:20 PM
To mitigate this constraint, SCGE researchers used a bacterial-based directed evolution assay combined with rational engineering to identify variants of Lachnospiraceae bacterium Cas12a with expanded PAM recognition. (2/3)
November 11, 2025 at 3:20 PM
Our hope is that these documents can be useful to investigators that are developing gene editing therapies for rare diseases.

#Regulatory #GeneTherapy #RareDisease #BiotechResearch #BiomedicalResearch
November 5, 2025 at 2:36 PM
The goal of the SCGE program is to accelerate the translation of genome editing therapies into the clinic. One of the ways we are working to achieve this goal is by publicly sharing successful strategies for starting clinical trials.
November 5, 2025 at 2:36 PM
This discussion builds on their work in which they created a bespoke corrective gene-editing therapy for an infant's severe urea cycle disorder, and highlights the importance of regulatory innovation.

#GeneTherapy #Platform #PersonalizedMedicine #Regulatory
October 31, 2025 at 1:13 PM
The AAV.k13 and AAV.k20 variants are promising vectors for therapeutic gene-transfer applications in kidney diseases and transplantation. (3/3)
October 28, 2025 at 1:42 PM
Here SCGE researchers show that new variants of adeno-associated viruses (AAVs) displaying robust and widespread transduction in the kidneys of mice, pigs and non-human-primates can be obtained by evolving capsid libraries via cross-species cycling in different kidney models. (2/3)
October 28, 2025 at 1:42 PM
Meet the Expert is a webinar series held by the Somatic Cell Genome Editing (SCGE) consortium to connect with experts involved in different aspects of gene therapy development and regulatory approval. Learn more at scge.mcw.edu/meet-the-exp...
SCGE Meet the Expert Webinar Series
Meet the Expert is a webinar series presented by the SCGE Consortium that aims to connect researchers with experts in the gene therapy space.
scge.mcw.edu
October 22, 2025 at 1:44 PM